---

---

tags : Trial    crawled date : 2022 - 03 - 16   

save search

---

DuPont to Participate at the J.P. Morgan 2022 Industrials Conference, Provides Supplemental 2022 Modeling Guidance
Published: 2022-03-16 (Crawled : 22:00) - prnewswire.com
DD | News | $73.53 0.6% 0.0% 1.9M |

Process Industries

| -1.9% | O: -1.64% H: 3.82% C: 3.82%
CE | News | $154.62 0.08% 0.0% 410K |

Process Industries

| 8.92% | O: -1.08% H: 1.5% C: 1.32%
als trials trial conference

---

LXP Industrial Trust Announces Quarterly Common Share Dividend
Published: 2022-03-16 (Crawled : 21:00) - globenewswire.com
LXP | $8.47 -0.7% 0.0% 1.6M |

Finance

| -44.61% | O: -0.32% H: 1.89% C: 1.11%
trial trust

---

Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published: 2022-03-16 (Crawled : 17:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 172.55% | O: 0.87% H: 0.27% C: -0.51%
pos kidney trial positive results positive results

---

First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with artificial intelligence (AI) technology versus standard colonoscopy
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
MDT | $79.19 0.14% 0.0% 6.1M |

Health Technology

| -23.89% | O: 1.99% H: 1.33% C: 1.26%
artificial intelligence technology trial intel endoscopy air technology

---

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 172.55% | O: 0.87% H: 0.27% C: -0.51%
jardiance pos kidney trial disease positive

---

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease
Published: 2022-03-16 (Crawled : 13:30) - biospace.com/
CRXT | $0.0475 |

| -92.7% | O: 0.23% H: 10.43% C: 7.06%
jatenzo treatment kidney trial disease one test

---

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-03-16 (Crawled : 13:30) - biospace.com/
BICX | $1.47 201.91% 200 |

Health Care and Social Assistan...

| -59.28% | O: 0.83% H: 0.0% C: 0.0%
bicx104 treatment implant order trial approval trex one opioid

---

Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial
Published: 2022-03-16 (Crawled : 13:00) - biospace.com/
ORMP | $2.19 -6.01% -6.39% 240K |

Health Technology

| -73.73% | O: 2.48% H: 4.79% C: 4.29%
phase 2 trial enroll insulin nash

---

Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Published: 2022-03-16 (Crawled : 12:30) - biospace.com/
MNMD | $8.92 -6.4% -6.84% 1.6M |

n/a

| 825.24% | O: 1.94% H: 3.81% C: 3.81%
trial lsd

---

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
OCUP | $1.675 -3.74% -3.88% 240K |

Health Technology

| -47.75% | O: 0.6% H: 3.28% C: 0.9%
apx3330 treatment phase 2 phase 2b trial 100 diabetic enroll diabetes

---

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
KPTI | $1.265 -8.33% -9.09% 1.3M |

Health Technology

| -77.81% | O: 0.8% H: 8.69% C: 6.38%
trial presentation cancer phase 3

---

Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
PTGX | $25.23 -1.33% -1.35% 390K |

Health Technology

| -0.97% | O: 2.01% H: 1.1% C: 0.57%
pn-235 phase 2 phase 2b trial therapeutics psoriasis one biotech iot milestone plague

---

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Published: 2022-03-16 (Crawled : 11:00) - globenewswire.com
ADAG | $2.53 -0.37% 1.8K |

Manufacturing

| -44.33% | O: 24.95% H: 0.0% C: -20.13%
adg126 safebody fda clearance phase 1b trial fda clearance phase 1 therapy antibody phase 2b

---

Seanergy and NYK Line Announce Successful Completion of Biofuel Trials on a Capesize Vessel
Published: 2022-03-16 (Crawled : 09:00) - globenewswire.com
PPRUF | News | $361.9 37.56% 4.3K |

Consumer Non-Durables

| -42.29% | O: -0.36% H: 6.42% C: 0.77%
PPRUY | News | $36.03 -0.11% 330K |

Manufacturing

| -41.33% | O: 3.96% H: 3.26% C: 2.47%
SHIP | $9.55 2.91% 2.83% 530K |

Miscellaneous

| 743.64% | O: 2.73% H: 4.42% C: 3.54%
als trials trial success

---

An Inside Look:  A Clinician’s Experience with the Waterlase Exclusive Trial Program
Published: 2022-03-15 (Crawled : 01:00) - biolase.com
BIOL | $0.145 -1.29% -1.31% 580K |

Health Technology

| -57.09% | O: 3.13% H: 4.55% C: 2.42%
program trial

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---